Effectiveness of Bedaquiline-, Delamanid- and Linezolid-Containing Regimens in Improving Treatment Outcomes Among Pediatric and Adolescents With Drug-Resistant Tuberculosis in the Country of Georgia

Résumé fourni par la source

BACKGROUND: Formulating effective regimens to treat children with drug-resistant tuberculosis (TB) remains a great challenge. We aimed to compare treatment outcomes among children treated with regimens containing newer second-line anti-TB drugs to those treated with previously used regimens. METHODS: We conducted a retrospective cohort study of individuals ≤18 years old treated for rifampicin-resistantTB in the country of Georgia from 2009 to 2023. We defined "new and repurposed second-line drugs (SLDs)" as regimens that contained bedaquiline, delamanid and/or linezolid; otherwise categorized as "traditional SLDs." We defined poor end-of-treatment outcomes if participants were lost to follow-up, experienced treatment failure or died during treatment. We defined poor long-term outcomes as TB recurrence and/or all-cause mortality after TB treatment completion. We reported relative risks and 95% confidence intervals (CIs) estimated with multivariable log-binomial regression models. RESULTS: We included 158 children and adolescents; 51 (32%) received new and repurposed SLDs and 107 (68%) received traditional SLDs. Poor end-of-treatment outcome was much less common among those who received new and repurposed SLDs compared with those who received traditional SLDs [1 (2%) vs. 18 (18%); adjusted risk ratio, 0.11 (95% CI, 0.01-0.50)]. Poor long-term outcomes occurred among 7 (4%) participants, including 4 [3% (95% CI, 0.8-6.0)] who had recurrent TB (2 received traditional SLDs and 2 received new and repurposed SLDs) and 3 [2% (95% CI, 0.5-5.1)] who died after TB treatment completion (all received traditional SLDs). CONCLUSIONS: Children and adolescents treated for rifampicin-resistant TB with new and repurposed drugs had much better treatment outcomes than those treated with traditional SLDs.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.